Panbela Therapeutics (Panbela Therapeutics) Operating Cash Flow per Share : $-210.32 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Operating Cash Flow per Share?

Panbela Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-3.00. Panbela Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-210.32.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 74.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 48.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Panbela Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

PBLA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 13.3 Med: 19.3 Max: 74.4
Current: 74.4

During the past 13 years, Panbela Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.40% per year. The lowest was 13.30% per year. And the median was 19.30% per year.

PBLA's 3-Year OCF Growth Rate is ranked better than
97.49% of 1234 companies
in the Biotechnology industry
Industry Median: 3.35 vs PBLA: 74.40

Panbela Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Panbela Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics Operating Cash Flow per Share Chart

Panbela Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-13,042.86

-13,764.29

-7,245.00

-7,638.00

-231.64

Panbela Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-750.08	-155.16	-45.73	-6.42	-3.00

Competitive Comparison of Panbela Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Panbela Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panbela Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Price-to-Operating-Cash-Flow falls into.

Panbela Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Panbela Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-25.249	/	0.109
	=	-231.64

Panbela Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-9.392	/	3.126
	=	-3.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-210.32

Panbela Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Panbela Therapeutics (Panbela Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Executives

Jennifer K. Simpson	director, officer: President and CEO	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath	officer: V.P. of Finance & CFO	4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob	director	712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer	director	712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust	10 percent owner	1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson	10 percent owner	130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel	director	712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill	director	712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen	officer: Chief Financial Officer	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen	director	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr	director
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen	director	712 VISTA BLVD, #305, WACONIA MN 55387